Li, Xi http://orcid.org/0000-0001-9185-7728
Poire, Alfonso http://orcid.org/0000-0001-8026-1689
Jeong, Kang Jin http://orcid.org/0000-0001-7552-4448
Zhang, Dong
Ozmen, Tugba Yildiran http://orcid.org/0000-0002-7861-6759
Chen, Gang
Sun, Chaoyang http://orcid.org/0000-0003-2469-1638
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Article History
Received: 21 November 2022
Accepted: 9 May 2024
First Online: 27 May 2024
Competing interests
: GBM SAB/Consultant: AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Lilly, Medacorp, Nanostring, PDX Pharmaceuticals, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals; Stock/Options/Financial: Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda, Turbine; Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nanostring. There is no competing interest declared by the other authors.